Baseline demographics and disease characteristics. All values are mean ± SD, unless otherwise indicated.
| Characteristic | MTX, n = 200 | ADA + MTX, n = 229 |
|---|---|---|
| Age, yrs | 52.8 ± 13.3 | 51.9 ± 14.1 |
| Female, n (%) | 146 (73.0) | 160 (69.9) |
| Rheumatoid factor-positive, n (%) | 170 (87.2) | 186 (83.8) |
| Duration of RA, yrs | 0.8 ± 0.9 | 0.7 ± 0.8 |
| Baseline DMARD use, n (%) | 59 (29.5) | 73 (31.7) |
| Baseline corticosteroid use, n (%) | 68 (34.0) | 81 (35.4) |
| DAS28-CRP, range 0–10a | 6.3 ± 0.8 | 6.3 ± 0.9 |
| DAS28-CRP ≥ 5.1, n (%)a | 182 (93.8) | 199 (90.9) |
| CRP, mg/dl | 4.0 ± 4.0 | 4.0 ± 4.2 |
| SJC (0–66 joints) | 22.4 ± 12.0 | 21.3 ± 11.5 |
| TJC (0–68 joints) | 32.0 ± 14.0 | 30.7 ± 14.6 |
| HAQ-DI (range 0–3) | 1.5 ± 0.7 | 1.5 ± 0.6 |
| mTSS (range 0–398) | 22.7 ± 22.7 | 18.6 ± 20.6 |
| Joint erosion score (0–230)b | 14.1 ± 13.7 | 11.3 ± 12.9 |
| Joint space narrowing score (0–168) | 8.6 ± 10.9 | 7.3 ± 9.4 |
↵a 195 and 220 patients from the MTX and ADA + MTX treatment groups, respectively, had DAS28-CRP values available at baseline.
↵b p = 0.03 for differences between MTX and ADA + MTX. MTX: methotrexate; ADA: adalimumab; RA: rheumatoid arthritis; DMARD: (nonbiologic) disease-modifying antirheumatic drug; DAS28: 28-joint Disease Activity Score; CRP: C-reactive protein; SJC: swollen joint count; TJC: tender joint count; HAQ-DI: Health Assessment Questionnaire-Disability Index; mTSS: modified total Sharp score.